ReviewMedicine international
Metastatic cancer detection and management with artificial intelligence and augmented reality (Review).
Review in Medicine international. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metastatic cancer remains a significant global health challenge, contributing to the majority of cancer-related mortality due to late detection, therapeutic resistance and the complexity of disseminated disease. Recent advances in artificial intelligence (AI) and augmented reality (AR) are transforming the landscape of metastatic cancer detection and management. AI-driven tools, including radiomics, deep learning models, and predictive analytics, enhance early identification of metastatic lesions, improve diagnostic accuracy, and support personalized treatment strategies by integrating multimodal clinical, imaging and molecular data. At the same time, AR technologies are increasingly applied in image-guided surgery, real-time tumor visualization and patient education, enabling more precise interventions and improved clinical decision-making. The combined use of AI and AR fosters multidisciplinary collaboration, facilitates comprehensive treatment planning, and may ultimately improve patient outcomes. However, despite these advancements, several challenges limit widespread implementation, including algorithmic bias, variability in data quality, concerns regarding patient privacy, and regulatory and ethical constraints. Furthermore, integration into clinical workflows requires robust validation, clinician training, and standardized guidelines. Future efforts are required to focus on developing transparent, generalizable AI models, strengthening data-security frameworks, and enhancing AR usability to ensure equitable, safe, and effective incorporation of these emerging technologies into metastatic cancer care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.